Effects of tibolone on the endometrium

References

• Benedek-Jaszmann IT Long-term placebo-controlled efficacy and safety study of Org 0D14 in climacteric women. Maturitas 1987;(Suppl 1): 25–33
   Google Scholar
• Egarter C, Huber J, Leikermoser R, et al. Tibo-lone versus conjugated estrogens and sequential progestogen in the treatment of climacteric com-plaints. Maturitas 1996;23:55–62
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart DM, Kraszewski A. A prospec-tive, double-blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteo-porosis. Br Med J 1980;280: 1207–9
   Google Scholar
• Berning B, Kuijk CV, Kuiper JW, Coelingh Bennink HJ, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996;19:395–9
   Google Scholar
• Bjarnason NH, Bjarnason K, Jaarbo J, Rosenquist C, Christiansen C. Tibolone: Preven-tion of bone loss in late postmenopausal women. J Gun Endocrinol Metab 1996;81:2419–22
   Google Scholar
• Pavlov PW, Ginsburg J, Kicovic PM, van der Schaaf DB, Prelevic G, Bennink HJ. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmeno-pausal osteoporotic women with and without previous fractures. Gynecol Endocrinol 1999;13: 230–7
   Google Scholar
• Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomized trial com-paring the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symp-toms. Br J Obstet Gynaecol 1998;105:904–11
   Google Scholar
• Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. Human endometrial 30-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of steroidal drugs. J Steroid Biochem Mol Biol 1993;45:345–51
   PubMed Web of Science ®Google Scholar
• Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progesta-genic effects of a steroidal drug (Org 0D14) and its metabolites on human endometrium. J Steroid Biochem Mol Biol 1990;35:535–41
   Web of Science ®Google Scholar
• Speroff L, Rowan J, Symons J, Gonant H, Wilborn W, for the CHART Study Group. Thecomparative effect on bone density, endo-metrium, and lipids of continuous hormones as replacement therapy (CHART study). J Am Med Assoc 1996;276:1397–03
   Google Scholar
• The Writing Group for the PEP Trial. Effect of hormone replacement therapy on endometrial histology in postmenopausal women. J Am Med Assoc 1996;275:370–5
   Google Scholar
• Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continu-ous combined oestrogen—progestogen replace-ment therapy. Br J Obstet Gynaecol 2000;107: 1392–400
   Google Scholar
• von Dadelszen P, Gillmer MDG, Gray MD, et al. Endometrial hyperplasia and adenocarcinoma during tibolone (Livial®) therapy. Br J Obstet Gynaecol 1994;101:158–61
   PubMedGoogle Scholar
• Punnonen R, Liukko P, Cortes-Prieto J, et al. Multicentre study of effects of Org 0D14 on endometrium, vaginal cytology and cervical mucus in postmenopausal and oophorectomized women. Maturitas 1984:5: 281–6
   Google Scholar
• Genazzani AR, Benedek-Jaszmann u, Hart DM, Andolsek L, Kicovic PM, Tax L. Org 0D14 and the endometrium. Maturitas 1991;13: 243–51
   Google Scholar
• Rymer J, Fogelman I, Chapman MG. The inci-dence of vaginal bleeding with tibolone treat-ment. Br J Obstet Gynaecol 1994;101:53–6
   Google Scholar
• Botsis D, Kassanos D, Kalogirou D, Antoniou G, Vitoratos N, Karakitsos P. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a compari-son. Maturitas 1997;26:57–62
   PubMed Web of Science ®Google Scholar
• Morris EP, Wilson POG, Robinson J, Rymer JM. Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999;106:954–9
   PubMedGoogle Scholar
• Kalogirou D, Botsis D, Antoniou G, Papdimitriou A, Papoulias J, Giannikos L. Endo-metrial safety during hormone replacement therapy: comparison of transvaginal sonography and endometrial biopsy. Menopause 1997;4: 161–6
   Web of Science ®Google Scholar
• Haenggi W, Bersinger NA, Alternatt HJ, Birkhauser MH. Comparison of transvaginal ultrasonography and endometrial biopsy inendometrial surveillance in postmenopausal HRT users. Maturitas 1997;27:133–43
   PubMed Web of Science ®Google Scholar
• Gredmark T, Kvint S, Havel G, Mattsson L. Histopathological findings in women with post-menopausal bleeding. Br J Obstet Gynaecol 1995;102:133–6
   PubMedGoogle Scholar
• Ginsburg J, Prelevic GM. Cause of vaginal bleed-ing in postmenopausal women taking tibolone. Maturitas 1996;24:107–10
   PubMed Web of Science ®Google Scholar
• Hourihan HM, Sheppard BL, Bonnar J. A morphometric study of the effect of oral norethisterone or levonorgestrel on endometrial blood vessels. Contraception 1986;34:603–12
   Google Scholar
• Presta M. Sex hormones modulate the synthesis of basic fibroblast growth factor in human endo-metrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. J Cell Physiol 1988;137:593–7
   PubMed Web of Science ®Google Scholar
• Ferriani RA, Charnock-Jones DS, Prentice A, Thomas EJ, Smith SK. Immunohistochemical localization of acidic and basic fibroblast growthfactors in normal human endometrium and endometriosis and the detection of their mRNA by polymerase chain reaction. Hum Reprod 1993;8:11–16
   PubMed Web of Science ®Google Scholar
• Shifren JL, Tseng JF, Zaloudek CJ, et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996;81:3112–18
   PubMed Web of Science ®Google Scholar
• Torry DS, Holt VJ, Keenan JA, Harris G, Caudle MR, Torry RJ. Vascular endothelial growth factor expression in cycling human endo-metrium. Fertil Steril 1996;66:72–80
   PubMed Web of Science ®Google Scholar
• Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial com-paring the effects of tibolone and continuous combined hormone replacement therapy in post-menopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904–11
   Google Scholar